Style Sampler

Layout Style

Patterns for Boxed Mode

Backgrounds for Boxed Mode

All fields are required.

Close Appointment form

Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation

  • Home
  • Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation

Research

Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of Symptoms Related to Chronic Inflammation

Jan 11, 2024 by BHI

No Comments

Safety Study of Intravenously Administered Human Cord Blood Stem Cells in the Treatment of symptoms Related to Chronic Inflammation.

Brian M. Mehling, Louis Quartararo, Marine Manvelyan, Paul Wang, Dong-Cheng Wu

 

Full Link

1

  • Share This

About the author

Related Posts

Submit a comment

Your email address will not be published. Required fields are marked *

Leave a Reply

You may use these HTML tags and attributes:

<a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>

About Blue Horizon International

Blue Horizon International is the world’s leading provider of adult and children’s stem cell therapies. We have safely and efficiently performed more than 4,000 stem cell therapies to date. We are the only treatment provider approved and associated with The Wuhan University Department of Medicine, The Biochemistry Institute of Wuhan University. We are fully licensed by the Ministry of Health of the Slovak Republic to offer cord blood, bone marrow and adipose stem cell derived treatments at Malacky Hospital near Bratislava, Slovakia.

Recent News
Address
Blue Horizon International, LLC 214 State Street, Suite 101 Hackensack, NJ 07601 | USA
Get in touch with us

© 2024 Blue Horizon International, LLC. All rights reserved. This website is only intended for consumers outside the United States.